Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARGO Therapeutics, Inc.CRGX · Entity 76319 | Director · President & CEO | March 14, 2025 | March 18, 2025 |
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARGO Therapeutics, Inc.
Report date March 14, 2025 · Filed March 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 303,905 |
Reported balance
After 2025-03-14 transaction · row 1
1 source rowRow 1 · 2025-03-14 · Grant · Acquired 200,000 · Balance 303,905 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/16th of the RSUs vest on each quarterly anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/16th of the RSUs vest on each quarterly anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
Entrada Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2036-06-10 | Direct | 19,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 17:16 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001689375-26-000043 · wk-form4_1781298996.xml · derivative · entry 1 Chapman Gina · CIK 0001989220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 08:04 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001689375-25-000030 · wk-form4_1749729890.xml · derivative · entry 1 Chapman Gina · CIK 0001989220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 11, 2025 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 16:16 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000069 · form4.xml · nonDerivative · entry 1 Chapman Gina · CIK 0001989220 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,905 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/16th of the RSUs vest on each quarterly anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 17:24 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,975 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001610717-24-000492 · form4.xml · derivative · entry 6 Chapman Gina · CIK 0001989220 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 549,515 Underlying: Common Stock · 2,975 shares Expires 2033-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 9, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 17:24 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | SaleCommon Stock | 2,975 | $25.03 | $74,456.81 |
DisclosureSEC source: 0001610717-24-000492 · form4.xml · nonDerivative · entry 4 Chapman Gina · CIK 0001989220 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,905 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 25, 2024. F3 · price: This transaction was executed in multiple trades in prices ranging from $25.00 to $25.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 17:24 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | Exercise / conversionCommon Stock | 2,975 | $5.03 | $14,964.25 |
DisclosureSEC source: 0001610717-24-000492 · form4.xml · nonDerivative · entry 3 Chapman Gina · CIK 0001989220 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 17:24 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,166 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001610717-24-000492 · form4.xml · derivative · entry 5 Chapman Gina · CIK 0001989220 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 552,490 Underlying: Common Stock · 7,166 shares Expires 2033-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 9, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 17:24 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | SaleCommon Stock | 7,166 | $25.09 | $179,774.88 |
DisclosureSEC source: 0001610717-24-000492 · form4.xml · nonDerivative · entry 2 Chapman Gina · CIK 0001989220 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,905 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 25, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $25.00 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 17:24 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | Exercise / conversionCommon Stock | 7,166 | $5.03 | $36,044.98 |
DisclosureSEC source: 0001610717-24-000492 · form4.xml · nonDerivative · entry 1 Chapman Gina · CIK 0001989220 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001689375-24-000034 · wk-form4_1718397205.xml · derivative · entry 1 Chapman Gina · CIK 0001989220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 13, 2024 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 16:20 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $25.07 | $0.00 |
DisclosureSEC source: 0001610717-24-000112 · form4.xml · derivative · entry 1 Chapman Gina · CIK 0001989220 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $15.41 | $0.00 |
DisclosureSEC source: 0001689375-23-000060 · wf-form4_169394589181133.xml · derivative · entry 1 Chapman Gina · CIK 0001989220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-09-01 F1 · derivative.exercise_date: The stock option shall vest in equal monthly installments over three years from the date of grant, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.